Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652716 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 377
- Enrollment target
NCT01652716 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 377 participants.
The verdict
NCT01652716, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 377 participants
- Enrollment target
Study Summary
To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus. To examine the long-term (52 weeks of treatment) safety and effect on glucose control of exenatide suspension administered once weekly in subjects with type 2 diabetes mellitus.
Interventions
- DRUG Exenatide once weekly suspension
- DRUG Exenatide twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01652716
The ClinicalTrials.gov registry entry for NCT01652716 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 377 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exenatide once weekly suspension is the first listed.
NCT01652716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01652716 about?
NCT01652716 is a clinical study titled "Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes". To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus. To examine the long-term (52 weeks of treatment) safety and effect on glucose control of ...
What is the current status of trial NCT01652716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 377 participants. The study started on 2013-01. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01652716?
The interventions under investigation include: Exenatide once weekly suspension (DRUG), Exenatide twice daily (DRUG).
Who is sponsoring clinical trial NCT01652716?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.